ストックスクリーナーアプリを入手
3.90
2.74%
-0.11
アフターアワーズ：
3.88
-0.02
-0.51%
前日終値:
$4.01
開ける：
$3.99
24時間の取引高:
138.92K
Relative Volume:
0.40
時価総額：
$210.42M
収益：
$2.76M
当期純損益:
$-49.12M
株価収益率:
-2.60
EPS:
-1.5
ネットキャッシュフロー:
$-46.21M
1週間 パフォーマンス:
-1.52%
1か月 パフォーマンス:
+57.26%
6か月 パフォーマンス:
+31.31%
1年 パフォーマンス:
-24.27%
1日の値動き範囲:
$3.81
$4.00
1週間の範囲:
$3.54
$4.10
52週間の値動き範囲:
$2.20
$6.50
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
名前
Orchestra Biomed Holdings Inc
セクター
電話
646-343-9298
住所
150 UNION SQUARE DRIVE, NEW HOPE
OBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
3.90 | 216.36M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-20 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-03-20 | 開始されました | BTIG Research | Buy |
| 2025-01-02 | 開始されました | Barclays | Overweight |
| 2024-08-22 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-25 | 開始されました | B. Riley Securities | Buy |
| 2024-01-19 | 開始されました | Jefferies | Buy |
| 2023-02-24 | 開始されました | Piper Sandler | Overweight |
| 2023-02-07 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Orchestra Biomed Holdings Inc (OBIO) 最新ニュース
What to expect from Orchestra BioMed Holdings Inc. in the next 30 daysPortfolio Return Summary & Verified Momentum Stock Watchlist - newser.com
Will Orchestra BioMed Holdings Inc. stock outperform tech sector in 20252025 Price Action Summary & Fast Entry Momentum Alerts - newser.com
Can Orchestra BioMed Holdings Inc. stock reach $100 price targetJuly 2025 Volume & Smart Investment Allocation Insights - newser.com
Exit strategy if you’re trapped in Orchestra BioMed Holdings Inc.Gap Down & Weekly Watchlist for Hot Stocks - newser.com
Will Orchestra BioMed Holdings Inc. stock beat EPS estimatesGap Down & Weekly Market Pulse Updates - newser.com
How sentiment analysis helps forecast Orchestra BioMed Holdings Inc.IPO Watch & AI Driven Stock Reports - newser.com
Custom watchlist performance reports with Orchestra BioMed Holdings Inc.2025 Top Gainers & Stepwise Trade Signal Implementation - newser.com
Will Orchestra BioMed Holdings Inc. stock recover after recent dropLayoff News & Scalable Portfolio Growth Methods - newser.com
How currency fluctuations impact Orchestra BioMed Holdings Inc. stock2025 Investor Takeaways & Weekly Top Gainers Alerts - newser.com
Is Orchestra BioMed Holdings Inc. reversing from oversold territoryRisk Management & Stepwise Trade Signal Implementation - newser.com
How to use a screener to detect Orchestra BioMed Holdings Inc. breakouts2025 Key Lessons & Weekly Top Gainers Trade List - newser.com
Certain Pre-Funded Warrants of Orchestra BioMed Holdings, Inc. are subject to a Lock-Up Agreement Ending on 31-OCT-2025. - MarketScreener
Certain Common Stock of Orchestra BioMed Holdings, Inc. are subject to a Lock-Up Agreement Ending on 31-OCT-2025. - MarketScreener
Orchestra BioMed Holdings, Inc. Announces Strategic Developments and Financial Milestones - TradingView
What drives Orchestra BioMed Holdings Inc stock priceMarket Depth Overview & Small Capital Portfolio Tips - earlytimes.in
Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial - HMP Global Learning Network
Orchestra BioMed, Terumo Sign $30 Million Strategic Agreements For Virtue SAB - Nasdaq
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements - TradingView
Orchestra BioMed (Nasdaq: OBIO) and Terumo in $30M ROFR deal on Virtue SAB; $20M preferred - Stock Titan
Orchestra Biomed’s New Study: A Game Changer in Coronary Treatment? - TipRanks
Orchestra BioMed announces first patients enrolled in Virtue® SAB US pivotal IDE coronary trial - MarketScreener
BRIEF-Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial - NewsX
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial - The Manila Times
Orchestra BioMed Announces First Patient Enrollments in Virtue Trial for Innovative Sirolimus AngioInfusion Balloon System - Quiver Quantitative
Orchestra BioMed (Nasdaq: OBIO) starts 740-patient U.S. IDE Virtue SAB coronary trial - Stock Titan
Orchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular Therapy - MSN
Orchestra Biomed Holdings Inc (OBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):